Parker, Jayson

Associate Director

Contact Information

Room: 
KN264
Mailing Address: 
3359 Mississauga Road
City: 
Mississauga
Province: 
ON
Postal Code: 
L5L 1C6
Jason Parker Photo

Jayson Parker is an Associate Director for the Master of Biotechnology Program.  He is also an Associate Professor (teaching stream) in the Department of Biology at the University of Toronto Mississauga and is cross appointed to the Institute of Biomaterials and Biomedical Engineering (IBBME) at the University of Toronto.  In addition, he lectures in the Faculty of Law.  He is currently a medical advisor to the hedge fund Burlington Capital.

Previously, he was a medical liaison operating in medical affairs for the pharmaceutical companies Novo Nordisk and Schering AG. 

He has worked in the investment banking industry as a buy side biotechnology stock analyst for Investor’s Group and Bolton Trembley.  He was the Director of Equity Research (medical) for AIC Limited (now Portland).

As a research associate, he has worked for the Addiction Research Foundation (now CAMH) on animal models of alcohol abuse.  In addition, he joined the medical imaging department at Sunnybrook Hospital and conducted research on Alzheimer patients through 3 dimensional reconstructions of patient brains from MRI scans.

He obtained his Ph.D. in Physiology (Neuroscience focus) based on his research on brain trauma at the University of Toronto and his MBA from Wilfried Laurier University.  His Masters degree from the University of Toronto focused on the neurobiology of cocaine addiction.

Lastly – he is an active Dungeons and Dragons player.

Research Areas

Clinical Trial failure rates - Quantification of the risk that trials will fail during clinical testing for specific patient populations.  We are now using advanced machine learning tools with a focus on biomarkers.

Digital Health - “Dark data” in health project explores how biometric data used in combination can predict the effect of lifestyle choices on performance within 24 hours with respect to cognition and physical performance.  This study is still in the data collection phase.

Medical Device Regulation - How products are regulated spanning medical devices, digital health products and health products.  Medical device ancestry of heart lung machines and digital health regulation are 2 projects nearing closure.

Publications

Rolfe, D., Parker, J. L., Morgan M (2016).  Are biosimilars patentable?  Expert Opinion in Therapeutic Patents.  26(8): 871-875.  Impact Factor 4.3

Tillie, N. J.L. Parker and  J. Feld (2016).  Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action," Canadian Journal of Gastroenterology and Hepatology, vol. 2016; 1-7.  Impact factor 2

Tam, T.Y.J, J.L. Parker, D. Anastasopulos, Balter, M.S (2016).  Clinical trial risk  in chronic obstructive pulmonary disease.  Journal of Respiration.  91(1): 79-86.  Impact Factor 3.5

Gasperis-Brigante, C, J.L. Parker, P.W. O’Conner and T.R. Bruno (2016).  Reducing clinical trial risk in multiple sclerosis. Multiple Sclerosis and Related Disorders.  January 2016 Volume 5, Pages 81–88. Impact factor 0.9